Seeking Alpha

DATROWAY® Continues to Show Promising Tumor Responses as Part of Combination Regimens in Patients with Early and Advanced Non-Small Cell Lung Cancer

TROPION-Lung02 and TROPION-Lung04 phase 1b results support combination of Daiichi Sankyo and AstraZeneca’s DATROWAY with immunotherapy as first-line treatment for advanced or metastatic NSCLC ...
Yahoo Finance

DATROWAY® (datopotamab deruxtecan-dlnk) improved OS and PFS in TROPION-Breast02

DATROWAY demonstrated statistically significant and clinically meaningful improvement in overall survival as 1st-line therapy for patients with metastatic triple-negative breast cancer for whom ...
Business Wire

DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated unprecedented median overall survival improvement of five months vs. chemo as 1st-line treatment for patients with ...

WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the TROPION-Breast02 Phase III trial showed DATROWAY ® (datopotamab deruxtecan-dlnk) demonstrated a statistically significant and clinically ...
Yahoo Finance

DATROWAY® Demonstrated an Unprecedented Median Overall Survival Improvement of Five Months Vs Chemotherapy as First-line Treatment for Patients with Metastatic Triple Negative ...

TOKYO & BASKING RIDGE, N.J., October 19, 2025--(BUSINESS WIRE)--Positive results from the TROPION-Breast02 phase 3 trial showed DATROWAY ® (datopotamab deruxtecan) demonstrated a statistically ...